To reduce cancer incidence and mortality through improved treatment and prevention by offering national state-of-the-art cancer research to the local communities.
Dayton was one of the initial members of the National Cancer Institute (NCI) Community Clinical Oncology Program.
Through clinical trials we hope to find better ways to prevent or treat cancer. Clinical trials test new approaches to surgery, radiation therapy, and chemotherapy.
Every treatment that is considered standard treatment today was established because patients entered clinical trials.
We are a regional non-profit cancer research consortium serving the Miami Valley area as well as Cincinnati, Findlay, Greenville, Middletown, Troy and Youngstown, Ohio; Northern Kentucky and Eastern Indiana.
Dayton Clinical Oncology Program, in cooperation with our participating area hospitals, universities and physicians, provides local access to national state-of-the-art cancer clinical trials through the National Cancer Institute and its Community Oncology Research Programs (NCORP).
Dayton Clinical Oncology Program, incorporated in 1983, became one of the initial members of the community oncology program. Today, we continue to offer NCI- funded clinical trials, as well as Foundation funded clinical trials for cancer.
The NCI Community Oncology Research Program (NCORP) is a national NCI-supported network that brings cancer treatment and cancer control and prevention clinical trials to people in their communities, while also looking at different aspects of cancer care with cancer care delivery research (CCDR).
In the early 1980's, the Federal Government found that over 85% of cancer patients were being treated in their local communities rather than at large cancer treatment centers.They initiated funding for the Community Clinical Oncology Program through the National Cancer Institute (NCI), one of the branches of the National Institutes of Health. Dayton Clinical Oncology Program was one of those original community sites, and has been providing access to national oncology clinical trials since 1983. In 2014, Dayton Clinical Oncology Program was awarded a five-year grant from the NCI, and is one of 46 community sites in the United States to transition from an NCI Community Clinical Oncology Program (CCOP) to an NCI Community Oncology Research Program (NCORP).
NCORP is comprised of 7 Research Bases and 46 Community Sites, 12 of which are designated as Minority/Underserved Community Sites. NCORP MU Community Sites have a patient population comprised of at least 30% racial/ethnic minorities or rural residents.
The NCORP Research Bases are hubs for the network that design and spearhead the conduct of multi-center clinical trials and CCDR, and provide overall administration, data management, scientific and statistical leadership, operational processes and personnel, and regulatory compliance.
The NCORP Community Sites accrue patients and participants to NCI-approved cancer clinical trials and research studies. The Sites are consortia of researchers, public hospitals, physician practices, academic medical centers, and other groups that provide healthcare services in communities across the U.S.
If you are interested in a clinical trial or would like more information about a clinical trial, speak with your oncologist, surgeon, family practice physician, or contact Dayton Clinical Oncology Program and we will be glad to assist you.
For a complete listing of our currently open clinical trials, go to the "Clinical Trials" tab. We maintain an active list of approximately 100 clinical trials for the treatment of cancers of the brain, breast, gastrointestinal, genitourinary, head and neck, leukemia, lung, lymphoma, melanoma, myeloma, sarcoma, and other sites, and for cancer prevention and cancer control and cancer care delivery research (CCDR).
The policy and procedures outlined are intended to meet the most recent requirements published by the federal government regarding revised Financial Conflict of Interest (FCOI) Regulation, Promoting Objectivity in Research on August 25, 2011 (42 CFR Part 50 Subpart F and 45 CFR Part 94).